TSR-033 is a Monoclonal Antibody owned by GSK, and is involved in 2 clinical trials, which are ongoing.
Monoclonal antibody elicits anti-neoplastic activity by inhibiting lymphocyte-activation gene 3 (LAG-3). LAG-3 is an inhibitory receptor that regulates T-cell function to promote tumoral immune escape. It also functions at multiple levels to ensure appropriate T-cell homeostasis, activation, and differentiation. The drug candidate targets the LAG-3 and inhibits the tumor-mediated immune suppression.
The revenue for TSR-033 is expected to reach a total of $1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the TSR-033 NPV Report.
TSR-033 is under development for the treatment of colorectal cancer, non-small cell lung cancer and metastatic melanoma. It targets lymphocyte-activation gene 3 (LAG-3). The drug candidate is developed based on the (Somatic hypermutation) SHM-XEL technology. It is also under development for ovarian cancer and endometrial cancer.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.
Quick View – TSR-033
|Highest Development Stage|